All Symptomatic Polycythemia Vera Patients may Benefit From Treatment With a JAK2 Inhibitor

Patients with polycythemia vera (PV) experience significant symptoms characterized by fatigue, itching, night sweats, bone pain, fever, and undesired weight loss that contribute to a poor quality of life. A recent study indicates the JAK2 inhibitor, ruxolitinib (Jakafi), alleviates these symptoms in many patients.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.